Skip to main content
spacbrain

REVELATION BIOSCIENCES, INC.

Closed (deSPAC)

Health Care · immunotherapeutics and diagnostics development

What it is
Biosciences Inc
What it’s doing now
Merging with Petra Acquisition Inc. (PAIC) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Biosciences Inc. Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development. REVTx-99b, the lead therapeutic candidate, is being developed for allergic rhinitis. REVDx‑501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation. Revelation has engaged MedWorld Advisors to facilitate partnering of the REVDx-501 asset. REVTx‑200 is an intranasal immunomodulator adjunct to be used in combination with a traditional intramuscular vaccination for more complete immunity. For more information on Revelation, please visit www.RevBiosciences.com .

Source: S-4/A, accession 0001213900-21-056625

What the company says about itself

Web research — not audited

Revelation Biosciences is a biotechnology company focused on rebalancing inflammation to optimize health. Its lead product, Gemini, is an intravenously administered proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®) designed to reduce damage associated with inflammation by reprogramming the innate immune system. The company is conducting Phase 2/3 TITAN studies for Gemini in Stage 2 and Stage 3 Acute Kidney Injury.

Markets:
Biotechnology | Pharmaceuticals
Products:
Gemini | PHAD®
What our web check found

[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "approximately $128 million Merger expected to close in Q4 2021" [https://www.businesswire.com/news/home/20210830005223/en/Revelation-Biosciences-Inc.-a-Life-Sciences-Company-Developing-Therapeutics-and-Diagnostics-for-Respiratory-Viral-Infections-Including-COVID-19-to-Become-Publicly-Traded-Through-a-Merger-with-Petra-Acquisition-Inc.]

Source: https://www.revbiosciences.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

REVELATION BIOSCIENCES, INC. is merging with Petra Acquisition Inc. (PAIC) currently marked Closed (deSPAC).

Headline equity value—

How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is REVELATION BIOSCIENCES, INC. going public?

REVELATION BIOSCIENCES, INC. has an approved merger with the SPAC Petra Acquisition Inc. (PAIC). Deal status: Closed (deSPAC).

Does REVELATION BIOSCIENCES, INC. have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals